Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov;1(4):428-37.
doi: 10.3978/j.issn.2225-319X.2012.11.07.

Systematic review of trimodality therapy for patients with malignant pleural mesothelioma

Affiliations

Systematic review of trimodality therapy for patients with malignant pleural mesothelioma

Christopher Cao et al. Ann Cardiothorac Surg. 2012 Nov.

Abstract

Background: Malignant pleural mesothelioma (MPM) is an aggressive form of cancer arising from the pleural mesothelium. Trimodality therapy (TMT) involving extrapleural pneumonectomy with neoadjuvant or adjuvant chemotherapy and adjuvant radiotherapy is a recognized treatment option with a curative intent. Despite encouraging results from institutional studies, TMT in the treatment of MPM remains controversial. The present systematic review aims to assess the safety and efficacy of TMT in the current literature.

Methods: A systematic review was performed using five electronic databases from 1 January 1985 to 1 October 2012. Studies were selected independently by two reviewers according to predefined selection criteria. The primary endpoint was overall survival. Secondary endpoints included disease-free survival, disease recurrence, perioperative morbidity and length of stay.

Results: Sixteen studies were included for quantitative assessment, including one randomized controlled trial and five prospective series. Median overall survival ranged from 12.8-46.9 months. Disease-free survival ranged from 10-16.3 months. Perioperative mortality ranged from 0-12.5%. Overall perioperative morbidity ranged from 50-82.6% and the average length of stay was 9-14 days.

Conclusions: Outcomes of patients who underwent TMT in the current literature appeared to be inconsistent. Four prospective series involving a standardised treatment regimen with neoadjuvant chemotherapy indicated encouraging results based on intention-to-treat analysis. However, a small study assessing the feasibility of conducting a randomized controlled trial for TMT versus conservative treatment reported poor short- and long-term outcomes for patients who underwent pneumonectomy. Overall, results of the present systematic review suggest TMT may offer acceptable perioperative outcomes and long-term survival in selected patients treated in specialized centers.

Keywords: Systematic review; extrapleural pneumonectomy; mesothelioma; trimodality therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Malignant pleural mesothelioma is a primary neoplasm originating from the mesothelial cells that may be associated with dyspnea, pleural effusion and/or chest pain
Figure 2
Figure 2
Search strategy of systematic review on trimodality therapy involving extrapleural pneumonectomy, chemotherapy and radiotherapy for patients with malignant pleural mesothelioma

References

    1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603 - PubMed
    1. Clements M, Berry G, Shi J, et al. Projected mesothelioma incidence in men in New South Wales. Occup Environ Med 2007;64:747-52 - PMC - PubMed
    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44 - PubMed
    1. Waite K, Gilligan D.The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clin Oncol (R Coll Radiol) 2007;19:182-7 - PubMed
    1. Rice D, Rusch V, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. J Thorac Oncol 2011;6:1304-12 - PubMed